Cooper Companies Forecasts 9.5% Earnings Growth to $4.51 Share in 2026
Cooper Companies holds a #2 analyst rank with a B-grade VGM Score and Growth Score B, forecasting 9.5% year-over-year earnings growth to $4.51 per share for fiscal 2026. The medical device firm's CooperVision and CooperSurgical segments drive premium contact lens share and expanding fertility, IVF and surgical device revenues.
1. Business Overview
Cooper Companies operates two main segments: CooperVision, focused on daily silicone hydrogel lenses, torics, multifocals and myopia management under the MyDay and MiSight franchises; and CooperSurgical, which provides fertility solutions including IVF, the Paragard contraceptive, and a range of office and surgical devices.
2. Analyst Ratings and Style Metrics
The company holds a #2 analyst ranking and receives B-grade ratings for both its VGM Score and Growth Score, reflecting a balanced mix of value, growth prospects and momentum characteristics.
3. Earnings Forecasts and Revisions
Fiscal 2026 consensus earnings per share have been lifted to $4.51, implying 9.5% year-over-year growth, supported by an average historical earnings surprise of +4.1% and at least one upward analyst revision in the last 60 days.